A citation-based method for searching scientific literature

Iciar Aviles-Olmos, John Dickson, Zinovia Kefalopoulou, Atbin Djamshidian, Peter Ell, Therese Soderlund, Peter Whitton, Richard Wyse, Tom Isaacs, Andrew Lees, Patricia Limousin, Thomas Foltynie. J Clin Invest 2013
Times Cited: 278







List of co-cited articles
1528 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial.
Dilan Athauda, Kate Maclagan, Simon S Skene, Martha Bajwa-Joseph, Dawn Letchford, Kashfia Chowdhury, Steve Hibbert, Natalia Budnik, Luca Zampedri, John Dickson,[...]. Lancet 2017
339
77

Motor and cognitive advantages persist 12 months after exenatide exposure in Parkinson's disease.
Iciar Aviles-Olmos, John Dickson, Zinovia Kefalopoulou, Atbin Djamshidian, Joshua Kahan, Peter Ell, Peter Whitton, Richard Wyse, Tom Isaacs, Andrew Lees,[...]. J Parkinsons Dis 2014
160
42

GLP-1 receptor stimulation preserves primary cortical and dopaminergic neurons in cellular and rodent models of stroke and Parkinsonism.
Yazhou Li, TracyAnn Perry, Mark S Kindy, Brandon K Harvey, David Tweedie, Harold W Holloway, Kathleen Powers, Hui Shen, Josephine M Egan, Kumar Sambamurti,[...]. Proc Natl Acad Sci U S A 2009
405
41


Peptide hormone exendin-4 stimulates subventricular zone neurogenesis in the adult rodent brain and induces recovery in an animal model of Parkinson's disease.
Göran Bertilsson, Cesare Patrone, Olof Zachrisson, Annica Andersson, Karin Dannaeus, Jessica Heidrich, Jarkko Kortesmaa, Alex Mercer, Elisabet Nielsen, Harriet Rönnholm,[...]. J Neurosci Res 2008
240
32

Block of A1 astrocyte conversion by microglia is neuroprotective in models of Parkinson's disease.
Seung Pil Yun, Tae-In Kam, Nikhil Panicker, SangMin Kim, Yumin Oh, Jong-Sung Park, Seung-Hwan Kwon, Yong Joo Park, Senthilkumar S Karuppagounder, Hyejin Park,[...]. Nat Med 2018
412
30

Glucagon-like peptide 1 receptor stimulation reverses key deficits in distinct rodent models of Parkinson's disease.
Alexander Harkavyi, Amjad Abuirmeileh, Rebecca Lever, Ann E Kingsbury, Christopher S Biggs, Peter S Whitton. J Neuroinflammation 2008
190
26

Utility of Neuronal-Derived Exosomes to Examine Molecular Mechanisms That Affect Motor Function in Patients With Parkinson Disease: A Secondary Analysis of the Exenatide-PD Trial.
Dilan Athauda, Seema Gulyani, Hanuma Kumar Karnati, Yazhou Li, David Tweedie, Maja Mustapic, Sahil Chawla, Kashfia Chowdhury, Simon S Skene, Nigel H Greig,[...]. JAMA Neurol 2019
94
27



In Alzheimer's Disease, 6-Month Treatment with GLP-1 Analog Prevents Decline of Brain Glucose Metabolism: Randomized, Placebo-Controlled, Double-Blind Clinical Trial.
Michael Gejl, Albert Gjedde, Lærke Egefjord, Arne Møller, Søren B Hansen, Kim Vang, Anders Rodell, Hans Brændgaard, Hanne Gottrup, Anna Schacht,[...]. Front Aging Neurosci 2016
204
25



The diabetes drug liraglutide prevents degenerative processes in a mouse model of Alzheimer's disease.
Paula L McClean, Vadivel Parthsarathy, Emilie Faivre, Christian Hölscher. J Neurosci 2011
467
21

Type 2 diabetes and the risk of Parkinson's disease.
Gang Hu, Pekka Jousilahti, Siamak Bidel, Riitta Antikainen, Jaakko Tuomilehto. Diabetes Care 2007
289
21


GLP-1 receptor stimulation reduces amyloid-beta peptide accumulation and cytotoxicity in cellular and animal models of Alzheimer's disease.
Yazhou Li, Kara B Duffy, Mary Ann Ottinger, Balmiki Ray, Jason A Bailey, Harold W Holloway, David Tweedie, Tracyann Perry, Mark P Mattson, Dimitrios Kapogiannis,[...]. J Alzheimers Dis 2010
229
20

Two novel dual GLP-1/GIP receptor agonists are neuroprotective in the MPTP mouse model of Parkinson's disease.
Peng Feng, Xiangjian Zhang, Dongfang Li, Chenhui Ji, Ziyue Yuan, Ruifang Wang, Guofang Xue, Guanglai Li, Christian Hölscher. Neuropharmacology 2018
52
38

A novel GLP-1/GIP dual agonist is more effective than liraglutide in reducing inflammation and enhancing GDNF release in the MPTP mouse model of Parkinson's disease.
Ziyue Yuan, Dongfang Li, Peng Feng, Guofang Xue, Chenhui Ji, Guanglai Li, Christian Hölscher. Eur J Pharmacol 2017
51
39


Parkinson's disease.
Lorraine V Kalia, Anthony E Lang. Lancet 2015
18

A novel neurotrophic property of glucagon-like peptide 1: a promoter of nerve growth factor-mediated differentiation in PC12 cells.
TracyAnn Perry, Debomoy K Lahiri, Demao Chen, Jie Zhou, Karen T Y Shaw, Josephine M Egan, Nigel H Greig. J Pharmacol Exp Ther 2002
233
17

Glucagon-like peptide-1 receptor is involved in learning and neuroprotection.
Matthew J During, Lei Cao, David S Zuzga, Jeremy S Francis, Helen L Fitzsimons, Xiangyang Jiao, Ross J Bland, Matthias Klugmann, William A Banks, Daniel J Drucker,[...]. Nat Med 2003
589
17


An anti-diabetes agent protects the mouse brain from defective insulin signaling caused by Alzheimer's disease- associated Aβ oligomers.
Theresa R Bomfim, Leticia Forny-Germano, Luciana B Sathler, Jordano Brito-Moreira, Jean-Christophe Houzel, Helena Decker, Michael A Silverman, Hala Kazi, Helen M Melo, Paula L McClean,[...]. J Clin Invest 2012
576
16


Post hoc analysis of the Exenatide-PD trial-Factors that predict response.
Dilan Athauda, Kate Maclagan, Natalia Budnik, Luca Zampedri, Steve Hibbert, Iciar Aviles-Olmos, Kashfia Chowdhury, Simon S Skene, Patricia Limousin, Thomas Foltynie. Eur J Neurosci 2019
28
53


A New Treatment Strategy for Parkinson's Disease through the Gut-Brain Axis: The Glucagon-Like Peptide-1 Receptor Pathway.
Dong Seok Kim, Ho-Il Choi, Yun Wang, Yu Luo, Barry J Hoffer, Nigel H Greig. Cell Transplant 2017
72
20

Parkinson's disease, insulin resistance and novel agents of neuroprotection.
Iciar Aviles-Olmos, Patricia Limousin, Andrew Lees, Thomas Foltynie. Brain 2013
185
15

Diabetes mellitus and Parkinson disease.
Gennaro Pagano, Sotirios Polychronis, Heather Wilson, Beniamino Giordano, Nicola Ferrara, Flavia Niccolini, Marios Politis. Neurology 2018
92
16

The diabetes drug liraglutide reverses cognitive impairment in mice and attenuates insulin receptor and synaptic pathology in a non-human primate model of Alzheimer's disease.
Andre F Batista, Leticia Forny-Germano, Julia R Clarke, Natalia M Lyra E Silva, Jordano Brito-Moreira, Susan E Boehnke, Andrew Winterborn, Brian C Coe, Ann Lablans, Juliana F Vital,[...]. J Pathol 2018
124
15

Diabetes and risk of Parkinson's disease: a systematic review and meta-analysis.
Emanuele Cereda, Michela Barichella, Carlo Pedrolli, Catherine Klersy, Erica Cassani, Riccardo Caccialanza, Gianni Pezzoli. Diabetes Care 2011
137
15

Protective effects of the GLP-1 mimetic exendin-4 in Parkinson's disease.
Dilan Athauda, Thomas Foltynie. Neuropharmacology 2018
49
28

Brain insulin resistance in type 2 diabetes and Alzheimer disease: concepts and conundrums.
Steven E Arnold, Zoe Arvanitakis, Shannon L Macauley-Rambach, Aaron M Koenig, Hoau-Yan Wang, Rexford S Ahima, Suzanne Craft, Sam Gandy, Christoph Buettner, Luke E Stoeckel,[...]. Nat Rev Neurol 2018
497
14

Association between diabetes and subsequent Parkinson disease: A record-linkage cohort study.
Eduardo De Pablo-Fernandez, Raph Goldacre, Julia Pakpoor, Alastair J Noyce, Thomas T Warner. Neurology 2018
108
14

Reduced incidence of Parkinson's disease after dipeptidyl peptidase-4 inhibitors-A nationwide case-control study.
Per Svenningsson, Karin Wirdefeldt, Li Yin, Fang Fang, Ioanna Markaki, Suad Efendic, Jonas F Ludvigsson. Mov Disord 2016
40
35

Evaluating the effects of the novel GLP-1 analogue liraglutide in Alzheimer's disease: study protocol for a randomised controlled trial (ELAD study).
Grazia Daniela Femminella, Eleni Frangou, Sharon B Love, Gail Busza, Clive Holmes, Craig Ritchie, Robert Lawrence, Brady McFarlane, George Tadros, Basil H Ridha,[...]. Trials 2019
68
20

Protection and reversal of excitotoxic neuronal damage by glucagon-like peptide-1 and exendin-4.
TracyAnn Perry, Norman J Haughey, Mark P Mattson, Josephine M Egan, Nigel H Greig. J Pharmacol Exp Ther 2002
264
13

What Effects Might Exenatide have on Non-Motor Symptoms in Parkinson's Disease: A Post Hoc Analysis.
Dilan Athauda, Kate Maclagan, Natalia Budnik, Luca Zampedri, Steve Hibbert, Simon S Skene, Kashfia Chowdhury, Iciar Aviles-Olmos, Patricia Limousin, Thomas Foltynie. J Parkinsons Dis 2018
30
43

Pharmacology, physiology, and mechanisms of incretin hormone action.
Jonathan E Campbell, Daniel J Drucker. Cell Metab 2013
811
13


Biology of incretins: GLP-1 and GIP.
Laurie L Baggio, Daniel J Drucker. Gastroenterology 2007
13

Diabetes medications and risk of Parkinson's disease: a cohort study of patients with diabetes.
Ruth Brauer, Li Wei, Tiantian Ma, Dilan Athauda, Christine Girges, Nirosen Vijiaratnam, Grace Auld, Cate Whittlesea, Ian Wong, Tom Foltynie. Brain 2020
42
30

Distribution and characterisation of Glucagon-like peptide-1 receptor expressing cells in the mouse brain.
Simon C Cork, James E Richards, Marie K Holt, Fiona M Gribble, Frank Reimann, Stefan Trapp. Mol Metab 2015
221
12

Insulin resistance impairs nigrostriatal dopamine function.
J K Morris, G L Bomhoff, B K Gorres, V A Davis, J Kim, P-P Lee, W M Brooks, G A Gerhardt, P C Geiger, J A Stanford. Exp Neurol 2011
91
13

Demonstrated brain insulin resistance in Alzheimer's disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline.
Konrad Talbot, Hoau-Yan Wang, Hala Kazi, Li-Ying Han, Kalindi P Bakshi, Andres Stucky, Robert L Fuino, Krista R Kawaguchi, Andrew J Samoyedny, Robert S Wilson,[...]. J Clin Invest 2012
12

Neuroprotective effects of a GIP analogue in the MPTP Parkinson's disease mouse model.
Yanwei Li, WeiZhen Liu, Lin Li, Christian Hölscher. Neuropharmacology 2016
50
24

Unimolecular dual incretins maximize metabolic benefits in rodents, monkeys, and humans.
Brian Finan, Tao Ma, Nickki Ottaway, Timo D Müller, Kirk M Habegger, Kristy M Heppner, Henriette Kirchner, Jenna Holland, Jazzminn Hembree, Christine Raver,[...]. Sci Transl Med 2013
319
12

Dementia is associated with insulin resistance in patients with Parkinson's disease.
Domenico Bosco, Massimiliano Plastino, Dario Cristiano, Carmela Colica, Caterina Ermio, Matteo De Bartolo, Pasquale Mungari, Giulia Fonte, Domenico Consoli, Arturo Consoli,[...]. J Neurol Sci 2012
80
15


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.